- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06221670
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)
January 14, 2024 updated by: Tianjin Medical University Cancer Institute and Hospital
Efficacy and Safety of Toripalimab Adjuvant Therapy in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) After Complete Resection: a Prospective, Single-arm Study
This is a prospective, open, single-center, single-arm phase II clinical study in non-small cell lung cancer (NSCLC) without common EGFR-sensitive mutations (Ex19del and L858R) or ALK fusion variants identified in the central laboratory.
To evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
51
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dongsheng Yue
- Phone Number: +8602223109106
- Email: yuedongsheng_cg@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The subjects will voluntarily sign the informed consent in person, and provide the informed consent before any specific study procedures;
- Male and female, ≥18 years old;
- Primary non-squamous NSCLC confirmed histologically by the central laboratory;
- The subject was clinically confirmed as stage IA2-IB by imaging with tumor lesion size > 2 cm;
- As confirmed by the central laboratory, the tumor contains no common EGFR mutations and ALK fusion variants;
- The primary NSCLC must be completely resected by surgery, and all lesions must be removed at the end of the surgery.All surgical margins must be negative. Lobectomy can be done with open surgery or thoracoscopic (VATS);
- Central laboratory pathology confirmed solid and/or micropapillary component ≥10%, and/or STAS, and/or pleural invasion, and/or poorly differentiated, and/or complex glands ≥ 10%; PD-L1 TPS ≥ 1% in tumor tissue;
- WHO physical status score is 0~1;
- Paraffin-embedded sections (10-15 sheets), or wax blocks or fresh frozen tissue for surgical resection of the lesion should be provided;
- Adequate bone marrow reserve or organ function (demonstrated by any of the following laboratory values: absolute neutrophil count ≥1.5×10⁹/L; Platelet count ≥100×10⁹/L; Hemoglobin ≥90 g/L; Alanine aminotransferase ≤ 2.5 ULN; Aspartate aminotransferase ≤2.5 times ULN; Total bilirubin ≤ 1.5 ULN; Serum creatinine ≤1.5 ULN with creatinine clearance ≥60 mL/min [as measured or calculated by Cockcroft and Gault formulas]);
- At least 2 weeks prior to initiation of the study drug, female subjects should be using highly effective contraceptive methods, pregnancy tests must be negative, and there must be no ongoing breastfeeding prior to initiation of the drug
- Subjects voluntarily join this study, with good compliance and cooperation in safety and survival follow-up.
Exclusion Criteria:
- Exposure to other antitumor therapies before enrollment;
- Patients who only received segmental resection and wedge resection;
- Patients with any history of active autoimmune disease or autoimmune disease;
- Complicated diseases that require the use of immunosuppressive drugs; concurrent diseases that require the use of immunosuppressive agents for systemic or locally absorbable corticosteroids;
- Combined with severe heart disease, or combined with New York Heart Association (NYHA) grade 3 or 4 cardiac insufficiency;
- Any evidence of prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or active interstitial lung disease;
- Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, any condition that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol, or active infections including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV);
- Have received preventive or attenuated vaccines within 4 weeks before the first administration;
- Patients are unsuitable for participation in this research after comprehensive assessment by the researchers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Toripalimab adjuvant therapy group
Patients must be enrolled within 8 weeks of complete surgical excision and receive Toripalimab at a dose of 240 mg intravenously (IV) once every 3 weeks for a planned duration of 1 years.
|
This is a prospective, open, single-center, single-arm phase II clinical study with no driver mutations identified in the central laboratory,to evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-year DFS rate
Time Frame: From date of randomisation up to approximately 5 years
|
DFS is defined as time from randomization to disease recurrence (determined by CT or MRI scan and/or pathologic disease on biopsy) or death (from any cause) by investigator assessment.
3-year DFS rate is Disease-Free Survival at 3 Years.
|
From date of randomisation up to approximately 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability in overall population
Time Frame: From date of randomisation up to approximately 10 years
|
AEs graded by CTCAE version 5.0
|
From date of randomisation up to approximately 10 years
|
DFS
Time Frame: From date of randomisation up to approximately 10 years
|
DFS is defined as time from randomization to disease recurrence (determined by CT or MRI scan and/or pathologic disease on biopsy) or death (from any cause) by investigator assessment.
|
From date of randomisation up to approximately 10 years
|
3-year OS rate
Time Frame: From date of randomization up to approximately 5 years
|
Defined as the percentage of patients alive at 3 years, respectively, estimated from a Kaplan Meier plot of OS at the time of the primary analysis
|
From date of randomization up to approximately 5 years
|
5-year OS rate
Time Frame: From date of randomization up to approximately 5 years
|
Defined as the percentage of patients alive at 5 years, respectively, estimated from a Kaplan Meier plot of OS at the time of the primary analysis
|
From date of randomization up to approximately 5 years
|
OS
Time Frame: From date of randomization up to approximately 10 years
|
OS is defined as the time from the date of randomisation until death due to any cause.
|
From date of randomization up to approximately 10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Dongsheng Yue, Tianjin Medical University Cancer Institute & Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 20, 2024
Primary Completion (Estimated)
March 20, 2026
Study Completion (Estimated)
March 20, 2031
Study Registration Dates
First Submitted
January 14, 2024
First Submitted That Met QC Criteria
January 14, 2024
First Posted (Actual)
January 24, 2024
Study Record Updates
Last Update Posted (Actual)
January 24, 2024
Last Update Submitted That Met QC Criteria
January 14, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NSCLC-Toripalimab-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on Toripalimab
-
Mabwell (Shanghai) Bioscience Co., Ltd.Not yet recruitingAdvanced Urothelial CarcinomaChina
-
Henan Cancer HospitalUnknownEsophageal Squamous Cell Carcinoma
-
Coherus Biosciences, Inc.Not yet recruitingAdvanced or Metastatic Solid Tumors
-
Sun Yat-sen UniversityThe First Affiliated Hospital of Guangzhou Medical University; Guangzhou Panyu...RecruitingStudy of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent ChemoradiotherapySmall Cell Lung Cancer Limited StageChina
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingLimited-stage Small Cell Lung Cancer (LS-SCLC)China, Taiwan, Georgia, United States
-
Qianfoshan HospitalRecruiting
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingAdvanced Solid TumorsChina
-
Harbour BioMed (Guangzhou) Co. Ltd.Not yet recruiting
-
Xinqiao Hospital of ChongqingChongqing University Cancer Hospital; Southwest Hospital, China; Daping Hospital...RecruitingNasopharyngeal CarcinomaChina
-
Sun YanShanghai Junshi Bioscience Co., Ltd.Not yet recruitingHypopharyngeal Neoplasm Malignant PrimaryChina